Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation strategies for once-weekly anti-obesity injections in obesity
jRCT1041260157Recruiting
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label trial of semaglutide and tirzepatide in obesity (2 arms). Primary endpoint: Percentage change in body weight from drug discontinuation to Week 24. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT1041260157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041260157.